Deerland is proud to announce that the FDA has issued a GRAS (Generally Recognized As Safe) No Objection Letter for its branded probiotic strain, Bacillus subtilis DE111®. A “Letter of No Objection” refers to the letter sent by the FDA confirming that they do not question the basis for the GRAS self-affirmation notification established and submitted by Deerland.
Through the GRAS notification program, companies voluntarily submit their self-affirmation documentation dossier, substantiated by extensive research and independent, qualified subject matter expert review, that a specific ingredient is Generally Recognized As Safe. The “Letter of No Objection” means that FDA has reviewed all of the scientific data on DE111, and has no questions or concerns regarding its safety.
“We are excited to receive the FDA’s no objection letter for DE111. It highlights the extensive research, including the clinical trials that have been conducted by our team, and we are proud of this accomplishment,” said Scott Ravech, CEO of Deerland.
In addition to the FDA letter, DE111 has previously received non-Novel Food status in both Canada and Australia, as well as approval as a natural health product ingredient by Health Canada, Further, DE111 is Star-K Kosher certified and Non-GMO Project verified.
About DE111® and Deerland Probiotics & Enzymes
DE111 is a genome sequenced and clinically tested strain of Bacillus subtilis, a probiotic spore that supports digestive and immune health. The genome sequencing confirmed the strain contained no plasmids, antibiotic resistant or deleterious genes; multiple human clinical studies support the strain’s benefits for digestive and immune health, including supporting regularity, controlling microbial populations in the gut while optimizing digestion, and improvements in body composition, strength and recovery in athletes. DE111 has the ability to form spores that protect the microbes from harsh conditions until they enter an environment ripe for germination, such as the GI tract. Because of this spore-forming ability, DE111 remains viable under a wide temperature and pH range, making it ideal for use in supplements as well as food and beverages.
Deerland Probiotics & Enzymes, based in Kennesaw, Ga., specializes in developing science-backed solutions that benefit microbiome health, using probiotic, prebiotic and enzyme technology. The company offers a line of unique, clinically supported branded products, including DE111®, PreforPro®, ProHydrolase®, Solarplast® and Glutalytic®. Deerland collaborates with customers to develop innovative and often proprietary solutions in the dietary supplement and food and beverage markets. In addition to branded ingredients and customized formulations, Deerland offers full turn key manufacturing services, including bulk blends, capsules, stick packs and tablets; as well as bottling and labeling. To contact Deerland Probiotics & Enzymes, call 800.697.8179 or visit www.deerland.com.
Join Deerland at booth 4524 at SupplySide West in Las Vegas!
Deerland has announced the publication of a clinical study demonstrating efficacy of the bacteriophage (phage) cocktail PreforPro® in favorably supporting the gut microbiota and systemic markers. PreforPro is patented for use as a prebiotic.
SupplySide West is coming to the Mandalay Bay Las Vegas November 6-10, 2018, and Deerland Probiotics & Enzymes is excited to be participating. Deerland will have two booths at the Expo Hall— Booth # 4937 as well as the former National Enzyme Company location (Booth # 5543). In addition, Deerland will offer a special presentation by John Deaton, Ph.D., vice president of science and technology, on the topic of the Role of Probiotics in Sports Nutrition.
KENNESAW, GA (September 27, 2018) – Deerland Enzymes, Inc. (Deerland), a global leader in probiotics and enzymes, announced today it will now operate as Deerland Probiotics & Enzymes. The name change was made to reflect the company’s broader probiotic and enzyme expertise and commitment to innovation.
“In light of our rapid growth in the probiotic space and the recent acquisition of National Enzyme Company, we feel that now is the time to freshen up our logo and make our company name more direct, concise and reflective of our commitment to both probiotic and enzyme-based formulations & science,” said Scott Ravech, CEO.
The US Food and Drug Administration has issued a draft guidance on labeling of live microbial ingredients (probiotics) as colony forming units (CFUs) in addition to weight, as is currently specified in the regulations.
Read more at nutraingredients-usa.com
A study demonstrating a new way to test for the presence of gluten in enzyme supplements has been published in the Journal of Nutrition & Food Sciences. The study was motivated by the growing demand for gluten free products and the need for accurate testing methodologies for products claiming to meet the “gluten free” standard of less than 20 ppm, according to co-author Dr. John Deaton, vice president of science and technology for Deerland Probiotics & Enzymes.
Deerland Probiotics & Enzymes has announced it has received FSSC 22000 certification as part of the company’s initiatives to be compliant with FDA’s new Food Safety Modernization Act of 2011 (FSMA). The certificate is applicable for the scope of design, development, manufacturing, packaging, testing and shipping of dietary supplements, feed supplements and other enzyme and probiotic-based formulations for human and animal consumption.
Deerland Probiotics & Enzymes announced on July 19th that the company had acquired National Enzyme Company (NEC). We believe this investment will allow us to bring even greater value to our customers and to the enzyme and probiotic industries we serve.
Deerland to Present Initial Results from Clinical Trial on DE111® Probiotic at the ISSN Sports Nutrition Conference
Deerland will share results from their latest clinical study at the International Society of Sports Nutrition (ISSN) 15th Annual Conference and Expo, which is held from June 7 to 9, 2018 in Clearwater Beach, FL. Dr. Jeremy R. Townsend of Lipscomb University in Nashville, TN will present preliminary data on Deerland’s exclusive strain of Bacillus subtilis DE111 titled “The Effect of Probiotic Supplementation on Markers of Immune and Endocrine Status in Division I Baseball Players.”